Is clinical research right for you?
In clinical research, patients with specific conditions volunteer to try a new medication or medical device that is evaluated for effectiveness of treating their disease. These medications and devices are studied by scientists and healthcare specialists, as well as an institutional review board (IRB) to ensure the study is safe and ethical for patients.
At AOCC, we are growing our research department and actively enrolling our patients in studies.
Take a look at our current clinical research studies:
PRIMA: A blood test that will be used to determine how a patient with RA may respond to various biologics groups.
Alumis Lumus: A long term trial that is investigating the use of ESK-001, a TYK2 inhibitor, for patients with Systemic Lupus. Click here to learn more: Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus (LUMUS)
Lavender: A year long trial that is investigating the response of patients with CLE to the biologic therapy, anifrolumab. Click here to learn more.
Be-Early: A long-term, Open-label trial to evaluate the effectiveness of treating newly diagnosed Systemic Lupus Erythematosus patients with Benlysta.
Observe: An observational trial to track the safety and efficacy of Benlysta in Patients with biopsy proven Lupus Nephritis.
Oasis 301: A new investigational biologic, Dazodalibep, that is being used to treat patients with Moderate to Severe Sjogren’s Syndrome.
IMVT: A new RA biologic for patients that have failed two or more biologic therapies and are seropositive.
RESOLVE: A new Mechanism of Action for a biologic medication that is being used to treat patients with a moderate disease primary Sjogren’s Syndrome.
DRI17821: An Oral TNF inhibitor for RA patients who are biologic naïve and currently taking Methotrexate.
PREDICT: A predictive blood biomarker trial for patients starting a JAK Inhibitor and have only been exposed to TNF therapies.
Reduce: A 12 month trial to access the efficacy and safety of a new oral medication for Gout patients
Artivia 03/05: A open label trial to access the safety and efficacy of allogeneic core blood-derived NK cell therapy in combination with lymphodepletion in patients with Lupus, Rheumatoid Arthritis, Sjogren’s, Idiopathic Inflammatory Myopathies and Systemic Scleroderma.
POETYK: A long term trial to assess the efficacy of an FDA approved medication, deucravacitinib, in patients with Lupus.
If you would like to learn more about enrolling in these trials, please call Audrey Droppelman at 704-631-3342 ext. 1170. You may also speak to your rheumatologist.